Greg McMahon, DO

As the treatment landscape continues to evolve, the expert faculty discuss how real-world considerations, including treatment access, insurance coverage, and patient costs, can significantly influence therapeutic decisions, sometimes as much as the clinical evidence itself.

As treatment options continue to expand, the expert faculty discuss where current evidence remains limited and identify key areas for future research that may further refine treatment selection and disease management.

This episode, titled “Emerging Treatment Strategies in mCSPC,” features panelists discussing the rapidly evolving treatment landscape in metastatic castration-sensitive prostate cancer (mCSPC) and the growing number of therapeutic approaches being incorporated alongside androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs).

In “Risk Stratification and Treatment Intensification Strategies in mCSPC,” our panel explores how clinicians use clinical, molecular, and genomic risk factors to personalize treatment decisions for patients with metastatic castration-sensitive prostate cancer (mCSPC). The expert faculty discuss how disease volume, timing of metastasis, tumor burden, PSA kinetics, and patient comorbidities influence risk stratification and guide the selection of doublet, triplet, and metastasis-directed treatment approaches.

Panelists explore how clinicians differentiate among available androgen receptor pathway inhibitor (ARPI)-based doublet therapies for patients with metastatic castration-sensitive prostate cancer (mCSPC).

Experts unpack evolving mCSPC care, from ARPIs and chemo to PARP and PSMA advances, plus guideline-driven, personalized therapy choices.

Panelists discuss how closing real-world evidence gaps through inclusive research and advanced data integration will refine sequencing strategies and improve outcomes for patients with mCSPC.

Panelists discuss how multidisciplinary collaboration and integration of RWE with NCCN guidelines strengthen ARPI adherence, sequencing, and continuity of care for patients with mCSPC.

Panelists discuss how proactive education, regular follow-up, and multidisciplinary support improve adherence to oral ARPI therapy and drive better real-world outcomes in mCSPC.

Panelists discuss how promoting transparency, methodological rigor, and clinical relevance helps overcome skepticism around real-world evidence and strengthens its role in guiding mCSPC care.

Panelists discuss how integrating high-quality real-world evidence with clinical trial data enhances confidence in treatment decisions and guides tailored ARPI selection for patients with mCSPC.

Panelists discuss how understanding the generalizability of real-world evidence and clearly communicating its differences from trial data help clinicians personalize treatment and build patient trust.

Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences.

Panelists discuss how recognizing and mitigating common biases in real-world prostate cancer data helps clinicians interpret findings responsibly and apply them effectively in patient care.

Panelists discuss how prednisone coadministration with abiraterone impacts tolerability and monitoring in patients with cardiometabolic comorbidities, guiding safer, personalized treatment choices in mCSPC.

Panelists discuss how real-world evidence comparing apalutamide and abiraterone, including the impact of prednisone use, informs balanced and patient-specific first-line treatment choices.

Panelists discuss how biomarker and molecular testing inform long-term planning in mCSPC, guiding future therapeutic sequencing and improving precision in patient management.

Panelists discuss how understanding pharmacologic and mechanistic distinctions among androgen receptor pathway inhibitors helps clinicians tailor therapy selection and patient monitoring.

Panelists discuss how understanding pharmacologic and mechanistic distinctions among androgen receptor pathway inhibitors helps clinicians tailor therapy selection and patient monitoring.

Panelists discuss how advances in systemic therapy have reshaped the treatment landscape for mCSPC, enabling more individualized and proactive first-line care.